Advanced

Treatment of malignant melanoma with dacarbazin (DTIC‐DOME) with special reference to urinary excretion of 5‐S‐cysteinyldopa

Jönsson, P. ‐E LU ; Agrup, G. LU ; Arnbjörnsson, E. LU ; Hafström, Lo and Rorsman, H. LU (1980) In Cancer 45(2). p.245-248
Abstract

Seventeen patients were given DTIC, 200 mg/m2/day in five‐day courses every four to six weeks. In four patients (stage II) treated on an adjuvant basis, tumor recurrence has been verified in three. Four of the palliatively treated patients were also given DTIC by regional intra‐arterial infusion with minimal positive tumor effect and minimal toxicity. 5‐S‐cysteinyldopa excretion in urine was checked continuously in all patients. Tumor recurrence was revealed in two patients given DTIC on an adjuvant basis three and four months before clinical signs of tumor. In the palliatively treated patients, 5‐S‐cysteinyldopa excretion increased in 5/6 patients judged to have stable disease, before tumor progression was clinically... (More)

Seventeen patients were given DTIC, 200 mg/m2/day in five‐day courses every four to six weeks. In four patients (stage II) treated on an adjuvant basis, tumor recurrence has been verified in three. Four of the palliatively treated patients were also given DTIC by regional intra‐arterial infusion with minimal positive tumor effect and minimal toxicity. 5‐S‐cysteinyldopa excretion in urine was checked continuously in all patients. Tumor recurrence was revealed in two patients given DTIC on an adjuvant basis three and four months before clinical signs of tumor. In the palliatively treated patients, 5‐S‐cysteinyldopa excretion increased in 5/6 patients judged to have stable disease, before tumor progression was clinically detectable. The use of 5‐S‐cysteinyldopa examination is a valuable adjunct to the follow‐up of the effect of DTIC therapy in melanoma patients.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer
volume
45
issue
2
pages
4 pages
publisher
John Wiley & Sons
external identifiers
  • scopus:0018916926
ISSN
0008-543X
language
English
LU publication?
yes
id
d40cc409-00b5-4e22-bb50-29542c0f95df
alternative location
https://onlinelibrary.wiley.com/doi/10.1002/1097-0142%2819800115%2945%3A2%3C245%3A%3AAID-CNCR2820450208%3E3.0.CO%3B2-%23
date added to LUP
2018-11-09 09:50:27
date last changed
2019-01-06 14:14:08
@article{d40cc409-00b5-4e22-bb50-29542c0f95df,
  abstract     = {<p>Seventeen patients were given DTIC, 200 mg/m<sup>2</sup>/day in five‐day courses every four to six weeks. In four patients (stage II) treated on an adjuvant basis, tumor recurrence has been verified in three. Four of the palliatively treated patients were also given DTIC by regional intra‐arterial infusion with minimal positive tumor effect and minimal toxicity. 5‐S‐cysteinyldopa excretion in urine was checked continuously in all patients. Tumor recurrence was revealed in two patients given DTIC on an adjuvant basis three and four months before clinical signs of tumor. In the palliatively treated patients, 5‐S‐cysteinyldopa excretion increased in 5/6 patients judged to have stable disease, before tumor progression was clinically detectable. The use of 5‐S‐cysteinyldopa examination is a valuable adjunct to the follow‐up of the effect of DTIC therapy in melanoma patients.</p>},
  author       = {Jönsson, P. ‐E and Agrup, G. and Arnbjörnsson, E. and Hafström, Lo and Rorsman, H.},
  issn         = {0008-543X},
  language     = {eng},
  month        = {01},
  number       = {2},
  pages        = {245--248},
  publisher    = {John Wiley & Sons},
  series       = {Cancer},
  title        = {Treatment of malignant melanoma with dacarbazin (DTIC‐DOME) with special reference to urinary excretion of 5‐S‐cysteinyldopa},
  volume       = {45},
  year         = {1980},
}